Date: 2011-06-27
Type of information: Development agreement
Compound: BL-7040
Company: BiolineRx (Israel) Yissum Research Development Company (Israel)
Therapeutic area: Inflammatory diseases
Type agreement: development
licensing
commercialisation
Action mechanism: BL-7040 has dual activity on both the nervous and immune systems, rendering it highly suitable for treating both neurological diseases and immune system related conditions such as inflammatory or autoimmune diseases. It was invented by Professor Hermona Soreq, from the Alexander Silberman Institute of Life Sciences, Faculty of Science and the Edmond and Lily Safra Center of Brain Sciences at the Hebrew University of Jerusalem. BL-7040 was previously developed for Myasthenia Gravis (MG), a neuromuscular disease, where it showed a high level of efficacy in Phase Ib and IIa clinical trials. However, after discovering a new mechanism of action for the drug, BioLineRx is designating BL-7040 for IBD and other inflammatory diseases with a much wider market.
Disease: inflammatory bowel disease
Details: * On June 27, 2011, BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, have announced that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
Financial terms:
Latest news:
